Virtus International Dividend ETF (VDI)
Live price chart, market sentiment, and community perspectives for Virtus International Dividend ETF (AMEX: VDI).
Live price chart, market sentiment, and community perspectives for Virtus International Dividend ETF (AMEX: VDI).
On our desk, we are looking closely at VDI's liquidity profile. With net assets hovering around $16.6M and a daily trading volume sitting at a mere 400 to 1,265 shares, execution is a clear bottleneck. Even though the 30-day median bid-ask spread is tight at 0.11%, you simply cannot scale into or out of this vehicle quickly without moving the price. The institutional footprint is microscopic—just 4 funds reporting positions in Q1 2026 totaling $13.9M. Until assets under management multiply significantly, this remains a watchlist item rather than a core allocation.
From a quantitative risk perspective, VDI presents an interesting mathematical setup. Danelfin's AI model flags it with an 8 out of 10 Buy score, translating to a +2.45% probability advantage over the broader ETF universe over a three-month horizon. Furthermore, its portfolio construction leans heavily into non-U.S. equities (99.68% allocation) within the Foreign Large Blend category. However, investors need to weigh this algorithmic optimism against the operational risk of a December 2025 inception date. Track records are short, and historical drawdowns under varying market regimes remain unproven.
In evaluating the fundamental mechanics of VDI for our strategy meetings, the systematic bottom-up approach focusing on behavioral finance inefficiencies is appealing on paper. The 0.39% expense ratio is entirely reasonable for an active international product, and the 2.88% 30-day SEC yield provides a baseline income return. When preparing pitches or answering allocation queries regarding this fund, analysts must emphasize that while the underlying factor profile targets undervalued international dividend payers, the fund's lack of a long-term performance history means clients must be comfortable with early-stage execution risks.
Explore plasma cleansing, somatic organ swaps, and BCI.